Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30101% above fair value
$3.81+0.03 (+0.79%)
Close on Nov 19, 2026Market cap $1.34BP/E –Yield –
Nuvation Bio gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Nuvation Bio's gross profit for the twelve months ending Sep 30, 2025 was $14.51M. For fiscal 2024 it was $795.00K.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $795.00K | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $9.77M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.26M | +2464.8% |
| Q1 FY2025 | Mar 31, 2025 | $990.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $1.50M | – |
| Q3 FY2024 | Sep 30, 2024 | -$788.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $88.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?